Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer
BACKGROUND p21(waf1/cip1) protein is a cyclin‐dependent kinase inhibitor able to arrest the cell cycle at the G1 phase by inhibiting DNA replication. The expression of p21(waf1/cip1) and its prognostic value in prostate cancer are largely unexplored. METHODS We used immunohistochemistry to analyze t...
Gespeichert in:
Veröffentlicht in: | The Prostate 1999-04, Vol.39 (1), p.8-15 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | BACKGROUND
p21(waf1/cip1) protein is a cyclin‐dependent kinase inhibitor able to arrest the cell cycle at the G1 phase by inhibiting DNA replication. The expression of p21(waf1/cip1) and its prognostic value in prostate cancer are largely unexplored.
METHODS
We used immunohistochemistry to analyze the expression of p21(waf1/cip1) in 213 prostate cancer cases, and the results were related to other known prognostic factors and patient survival during a long‐term follow‐up.
RESULTS
The expression of p21 (waf1/cip1) protein was significantly associated with high Gleason score (P = 0.001), DNA aneuploidy (P = 0.013), high S‐phase fraction (P = 0.019), and expression of Ki‐67 (P = 0.021) and bcl‐2 (P = 0.001) as well as cyclin A (P = 0.035) and D proteins (P < 0.001). In univariate survival analysis the signal of p21(waf1/cip1) was significantly related to unfavorable prognosis (P = 0.010) both in the entire cohort and in local tumors (P = 0.034). In multivariate analysis, M‐category, clinical T‐category, Gleason score, and patient age were independent prognostic factors. In local tumors the expression of p21(waf1/cip1) together with clinical T‐category and S‐phase fraction were significant independent predictors of cancer related survival.
CONCLUSIONS
The results suggest that the expression of p21(waf1/cip1) protein is associated both with cell proliferation and patient survival in prostate cancer. Prostate 39:8–15, 1999. © 1999 Wiley‐Liss, Inc. |
---|---|
ISSN: | 0270-4137 1097-0045 |
DOI: | 10.1002/(SICI)1097-0045(19990401)39:1<8::AID-PROS2>3.0.CO;2-N |